Coagulopathy of Coronavirus Disease 2019

Recent studies have reported a high prevalence of thrombotic events in coronavirus disease 2019. However, the significance of thromboembolic complications has not been widely appreciated. The purpose of this review is to provide current knowledge of this serious problem. Narrative review. Online sea...

Full description

Saved in:
Bibliographic Details
Published in:Critical care medicine Vol. 48; no. 9; p. 1358
Main Authors: Iba, Toshiaki, Levy, Jerrold H, Levi, Marcel, Connors, Jean Marie, Thachil, Jecko
Format: Journal Article
Language:English
Published: United States 01.09.2020
Subjects:
ISSN:1530-0293, 1530-0293
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Recent studies have reported a high prevalence of thrombotic events in coronavirus disease 2019. However, the significance of thromboembolic complications has not been widely appreciated. The purpose of this review is to provide current knowledge of this serious problem. Narrative review. Online search of published medical literature through PubMed using the term "COVID-19," "SARS," "acute respiratory distress syndrome," "coronavirus," "coagulopathy," "thrombus," and "anticoagulants." Articles were chosen for inclusion based on their relevance to coagulopathy and thrombosis in coronavirus disease 2019, and anticoagulant therapy. Reference lists were reviewed to identify additional relevant articles. Coronavirus disease 2019 is associated with a strikingly high prevalence of coagulopathy and venous thromboembolism that may contribute to respiratory deterioration. Monitoring coagulation variables is important, as abnormal coagulation tests are related to adverse outcomes and may necessitate adjuvant antithrombotic interventions. In the initial phase of the infection, D-dimer and fibrinogen levels are increased, while activated partial prothrombin time, prothrombin time, and platelet counts are often relatively normal. Increased D-dimer levels three times the upper limit of normal may trigger screening for venous thromboembolism. In all hospitalized patients, thromboprophylaxis using low-molecular-weight heparin is currently recommended. The etiology of the procoagulant responses is complex and thought to be a result of specific interactions between host defense mechanisms and the coagulation system. Although the coagulopathy is reminiscent of disseminated intravascular coagulation and thrombotic microangiopathy, it has features that are markedly distinct from these entities. Severe acute respiratory syndrome coronavirus 2/coronavirus disease 2019 frequently induces hypercoagulability with both microangiopathy and local thrombus formation, and a systemic coagulation defect that leads to large vessel thrombosis and major thromboembolic complications, including pulmonary embolism in critically ill hospitalized patients. D-dimers and fibrinogen levels should be monitored, and all hospitalized patients should undergo thromboembolism prophylaxis with an increase in therapeutic anticoagulation in certain clinical situations.
AbstractList Recent studies have reported a high prevalence of thrombotic events in coronavirus disease 2019. However, the significance of thromboembolic complications has not been widely appreciated. The purpose of this review is to provide current knowledge of this serious problem. Narrative review. Online search of published medical literature through PubMed using the term "COVID-19," "SARS," "acute respiratory distress syndrome," "coronavirus," "coagulopathy," "thrombus," and "anticoagulants." Articles were chosen for inclusion based on their relevance to coagulopathy and thrombosis in coronavirus disease 2019, and anticoagulant therapy. Reference lists were reviewed to identify additional relevant articles. Coronavirus disease 2019 is associated with a strikingly high prevalence of coagulopathy and venous thromboembolism that may contribute to respiratory deterioration. Monitoring coagulation variables is important, as abnormal coagulation tests are related to adverse outcomes and may necessitate adjuvant antithrombotic interventions. In the initial phase of the infection, D-dimer and fibrinogen levels are increased, while activated partial prothrombin time, prothrombin time, and platelet counts are often relatively normal. Increased D-dimer levels three times the upper limit of normal may trigger screening for venous thromboembolism. In all hospitalized patients, thromboprophylaxis using low-molecular-weight heparin is currently recommended. The etiology of the procoagulant responses is complex and thought to be a result of specific interactions between host defense mechanisms and the coagulation system. Although the coagulopathy is reminiscent of disseminated intravascular coagulation and thrombotic microangiopathy, it has features that are markedly distinct from these entities. Severe acute respiratory syndrome coronavirus 2/coronavirus disease 2019 frequently induces hypercoagulability with both microangiopathy and local thrombus formation, and a systemic coagulation defect that leads to large vessel thrombosis and major thromboembolic complications, including pulmonary embolism in critically ill hospitalized patients. D-dimers and fibrinogen levels should be monitored, and all hospitalized patients should undergo thromboembolism prophylaxis with an increase in therapeutic anticoagulation in certain clinical situations.
Recent studies have reported a high prevalence of thrombotic events in coronavirus disease 2019. However, the significance of thromboembolic complications has not been widely appreciated. The purpose of this review is to provide current knowledge of this serious problem.OBJECTIVESRecent studies have reported a high prevalence of thrombotic events in coronavirus disease 2019. However, the significance of thromboembolic complications has not been widely appreciated. The purpose of this review is to provide current knowledge of this serious problem.Narrative review.DESIGNNarrative review.Online search of published medical literature through PubMed using the term "COVID-19," "SARS," "acute respiratory distress syndrome," "coronavirus," "coagulopathy," "thrombus," and "anticoagulants."DATA SOURCESOnline search of published medical literature through PubMed using the term "COVID-19," "SARS," "acute respiratory distress syndrome," "coronavirus," "coagulopathy," "thrombus," and "anticoagulants."Articles were chosen for inclusion based on their relevance to coagulopathy and thrombosis in coronavirus disease 2019, and anticoagulant therapy. Reference lists were reviewed to identify additional relevant articles.STUDY SELECTION AND DATA EXTRACTIONArticles were chosen for inclusion based on their relevance to coagulopathy and thrombosis in coronavirus disease 2019, and anticoagulant therapy. Reference lists were reviewed to identify additional relevant articles.Coronavirus disease 2019 is associated with a strikingly high prevalence of coagulopathy and venous thromboembolism that may contribute to respiratory deterioration. Monitoring coagulation variables is important, as abnormal coagulation tests are related to adverse outcomes and may necessitate adjuvant antithrombotic interventions. In the initial phase of the infection, D-dimer and fibrinogen levels are increased, while activated partial prothrombin time, prothrombin time, and platelet counts are often relatively normal. Increased D-dimer levels three times the upper limit of normal may trigger screening for venous thromboembolism. In all hospitalized patients, thromboprophylaxis using low-molecular-weight heparin is currently recommended. The etiology of the procoagulant responses is complex and thought to be a result of specific interactions between host defense mechanisms and the coagulation system. Although the coagulopathy is reminiscent of disseminated intravascular coagulation and thrombotic microangiopathy, it has features that are markedly distinct from these entities.DATA SYNTHESISCoronavirus disease 2019 is associated with a strikingly high prevalence of coagulopathy and venous thromboembolism that may contribute to respiratory deterioration. Monitoring coagulation variables is important, as abnormal coagulation tests are related to adverse outcomes and may necessitate adjuvant antithrombotic interventions. In the initial phase of the infection, D-dimer and fibrinogen levels are increased, while activated partial prothrombin time, prothrombin time, and platelet counts are often relatively normal. Increased D-dimer levels three times the upper limit of normal may trigger screening for venous thromboembolism. In all hospitalized patients, thromboprophylaxis using low-molecular-weight heparin is currently recommended. The etiology of the procoagulant responses is complex and thought to be a result of specific interactions between host defense mechanisms and the coagulation system. Although the coagulopathy is reminiscent of disseminated intravascular coagulation and thrombotic microangiopathy, it has features that are markedly distinct from these entities.Severe acute respiratory syndrome coronavirus 2/coronavirus disease 2019 frequently induces hypercoagulability with both microangiopathy and local thrombus formation, and a systemic coagulation defect that leads to large vessel thrombosis and major thromboembolic complications, including pulmonary embolism in critically ill hospitalized patients. D-dimers and fibrinogen levels should be monitored, and all hospitalized patients should undergo thromboembolism prophylaxis with an increase in therapeutic anticoagulation in certain clinical situations.CONCLUSIONSSevere acute respiratory syndrome coronavirus 2/coronavirus disease 2019 frequently induces hypercoagulability with both microangiopathy and local thrombus formation, and a systemic coagulation defect that leads to large vessel thrombosis and major thromboembolic complications, including pulmonary embolism in critically ill hospitalized patients. D-dimers and fibrinogen levels should be monitored, and all hospitalized patients should undergo thromboembolism prophylaxis with an increase in therapeutic anticoagulation in certain clinical situations.
Author Iba, Toshiaki
Levi, Marcel
Thachil, Jecko
Levy, Jerrold H
Connors, Jean Marie
Author_xml – sequence: 1
  givenname: Toshiaki
  surname: Iba
  fullname: Iba, Toshiaki
  organization: Department of Emergency and Disaster Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan
– sequence: 2
  givenname: Jerrold H
  surname: Levy
  fullname: Levy, Jerrold H
  organization: Department of Anesthesiology, Critical Care, and Surgery, Duke University School of Medicine, Durham, NC
– sequence: 3
  givenname: Marcel
  surname: Levi
  fullname: Levi, Marcel
  organization: Department of Medicine and Cardio-metabolic Programme-NIHR UCLH/UCL BRC, University College London Hospitals NHS Foundation Trust, London, United Kingdom
– sequence: 4
  givenname: Jean Marie
  surname: Connors
  fullname: Connors, Jean Marie
  organization: Hematology Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
– sequence: 5
  givenname: Jecko
  surname: Thachil
  fullname: Thachil, Jecko
  organization: Department of Haematology, Manchester Royal Infirmary, Manchester, United Kingdom
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32467443$$D View this record in MEDLINE/PubMed
BookMark eNpNj01Lw0AYhBep2A_9ByI59pK6u-9-HmWtH1Dxouew2bzRSJKt2Ubov7dghQ4MM4eHgZmTSR97JOSa0RWjVt8697KiJxJCmjMyYxJoTrmFyUmfknlKX5QyITVckClwobQQMCNLF_3H2Mat333us1hnLg6x9z_NMKbsvknoE2acMntJzmvfJrw65oK8P6zf3FO-eX18dnebPEhlTF5LpcvSK8RQIi2DqFWQopIeKEAF_mBujLFoQwkGhAIUlmuDYLzhleILsvzb3Q7xe8S0K7omBWxb32McU8EFNcxKzcwBvTmiY9lhVWyHpvPDvvh_x38BTnNRfA
CitedBy_id crossref_primary_10_1016_j_jinf_2021_01_003
crossref_primary_10_1097_APO_0000000000000358
crossref_primary_10_1177_02676591211001791
crossref_primary_10_1055_s_0040_1715798
crossref_primary_10_1007_s00392_023_02240_1
crossref_primary_10_3390_jcm10143086
crossref_primary_10_1016_j_rpth_2023_102203
crossref_primary_10_1097_MCC_0000000000000861
crossref_primary_10_1186_s12890_023_02521_5
crossref_primary_10_3390_ijms232315136
crossref_primary_10_1016_j_imlet_2021_01_001
crossref_primary_10_1097_CCM_0000000000004545
crossref_primary_10_3390_jcm11123443
crossref_primary_10_1007_s10067_021_05580_3
crossref_primary_10_1016_j_vph_2024_107444
crossref_primary_10_1111_aor_13940
crossref_primary_10_1182_bloodadvances_2020003046
crossref_primary_10_1177_10760296221086286
crossref_primary_10_1164_rccm_202111_2661CP
crossref_primary_10_1016_j_nwh_2022_11_004
crossref_primary_10_3389_fphys_2024_1474707
crossref_primary_10_1002_rth2_12597
crossref_primary_10_1080_10408363_2023_2232010
crossref_primary_10_1016_j_lfs_2020_118431
crossref_primary_10_1186_s12883_025_04019_5
crossref_primary_10_1111_ijlh_13547
crossref_primary_10_3389_fimmu_2020_01841
crossref_primary_10_1007_s00259_020_04999_1
crossref_primary_10_1097_CCM_0000000000004895
crossref_primary_10_1371_journal_pone_0257376
crossref_primary_10_1055_s_0044_1782660
crossref_primary_10_1038_s41598_024_69212_x
crossref_primary_10_1097_CCM_0000000000004530
crossref_primary_10_1016_j_jor_2025_06_031
crossref_primary_10_3389_fmed_2025_1649217
crossref_primary_10_4103_ijmr_IJMR_3841_20
crossref_primary_10_1097_MD_0000000000042747
crossref_primary_10_3389_fimmu_2022_978977
crossref_primary_10_1177_08850666211051960
crossref_primary_10_3390_pathogens9060493
crossref_primary_10_3390_microorganisms11122940
crossref_primary_10_1016_j_hermed_2024_100923
crossref_primary_10_4103_1673_5374_327323
crossref_primary_10_5114_ait_2021_105783
crossref_primary_10_1016_j_rpth_2023_100042
crossref_primary_10_3390_ijms23136880
crossref_primary_10_3390_life15091399
crossref_primary_10_1016_j_cytogfr_2021_10_007
crossref_primary_10_1016_j_rccar_2020_08_003
crossref_primary_10_1097_MD_0000000000024409
crossref_primary_10_1007_s11094_021_02437_6
crossref_primary_10_1002_jcu_23160
crossref_primary_10_1001_jamainternmed_2021_6203
crossref_primary_10_1371_journal_pone_0262600
crossref_primary_10_1016_j_chest_2021_06_016
crossref_primary_10_1016_j_ajpath_2021_04_010
crossref_primary_10_3389_fneur_2020_00806
crossref_primary_10_1016_j_arcmed_2021_07_003
crossref_primary_10_1007_s10238_021_00787_9
crossref_primary_10_3389_fncel_2020_00229
crossref_primary_10_1016_j_ajog_2020_07_049
crossref_primary_10_1007_s40265_020_01377_x
crossref_primary_10_3390_ph16040584
crossref_primary_10_1161_CIRCULATIONAHA_120_050754
crossref_primary_10_3390_life14020237
crossref_primary_10_1016_j_heliyon_2022_e11536
crossref_primary_10_4103_njcp_njcp_1633_21
crossref_primary_10_1177_1753495X231206931
crossref_primary_10_3390_biomedicines12030636
crossref_primary_10_1007_s00392_020_01766_y
crossref_primary_10_3389_fmed_2020_598379
crossref_primary_10_3390_life12111924
crossref_primary_10_1097_MD_0000000000031040
crossref_primary_10_1016_j_clinimag_2020_11_054
crossref_primary_10_1016_j_tjog_2022_06_012
crossref_primary_10_1097_CCE_0000000000000670
crossref_primary_10_1038_s41581_020_00356_5
crossref_primary_10_1016_j_jped_2020_10_008
crossref_primary_10_1016_j_csbj_2021_06_041
crossref_primary_10_1186_s12959_022_00428_5
crossref_primary_10_1097_CCM_0000000000004616
crossref_primary_10_1016_j_prrv_2020_06_004
crossref_primary_10_1097_SHK_0000000000002021
crossref_primary_10_1515_dx_2020_0078
crossref_primary_10_7759_cureus_38067
crossref_primary_10_1038_s41598_020_80120_8
crossref_primary_10_1038_s41598_022_08026_1
crossref_primary_10_1002_cpdd_1446
crossref_primary_10_1007_s12185_020_03029_y
crossref_primary_10_3390_ijms241612782
crossref_primary_10_1097_CCE_0000000000000567
crossref_primary_10_1308_rcsann_2021_0342
crossref_primary_10_3389_fphar_2022_849628
crossref_primary_10_1016_j_rmcr_2022_101674
crossref_primary_10_2147_RMHP_S281388
crossref_primary_10_1155_2022_8997709
crossref_primary_10_3233_CH_221491
crossref_primary_10_12968_hmed_2021_0112
crossref_primary_10_1038_s41569_021_00665_7
crossref_primary_10_1542_peds_2020_049793
crossref_primary_10_1016_j_prostaglandins_2022_106619
crossref_primary_10_3390_ijms25137209
crossref_primary_10_1111_ijlh_13500
crossref_primary_10_1177_0885066621997039
crossref_primary_10_3390_molecules27144327
crossref_primary_10_4103_lungindia_lungindia_919_20
crossref_primary_10_1097_CCM_0000000000004971
crossref_primary_10_3390_biomedicines11082301
crossref_primary_10_1016_j_heliyon_2021_e06033
crossref_primary_10_1016_j_tjog_2022_03_047
crossref_primary_10_1007_s11239_021_02593_2
crossref_primary_10_1055_a_1325_0268
crossref_primary_10_1186_s12959_021_00280_z
crossref_primary_10_3389_fcimb_2021_679878
crossref_primary_10_2147_JBM_S321372
crossref_primary_10_1055_a_1346_3178
crossref_primary_10_1016_j_smhs_2020_09_002
crossref_primary_10_4103_IJO_IJO_626_23
crossref_primary_10_1007_s43032_023_01312_x
crossref_primary_10_3390_s21082636
crossref_primary_10_1080_1744666X_2021_1847640
crossref_primary_10_1016_j_prp_2024_155251
crossref_primary_10_1055_a_2043_8628
crossref_primary_10_1177_0885066620964392
crossref_primary_10_1007_s10555_022_10019_5
crossref_primary_10_1016_j_tcm_2020_10_011
crossref_primary_10_1182_bloodadvances_2021005210
crossref_primary_10_1177_10600280211025042
crossref_primary_10_1080_17843286_2023_2204593
crossref_primary_10_3390_molecules26092618
crossref_primary_10_1111_dth_14053
crossref_primary_10_1111_jth_15294
crossref_primary_10_1007_s11239_021_02461_z
crossref_primary_10_1186_s12959_022_00432_9
crossref_primary_10_3390_diagnostics13152508
crossref_primary_10_1053_j_jvca_2021_10_011
crossref_primary_10_1016_j_jemermed_2021_04_030
crossref_primary_10_1016_j_jpha_2021_09_009
crossref_primary_10_1097_CCM_0000000000004509
crossref_primary_10_3390_math11020289
crossref_primary_10_1016_j_carbpol_2024_122930
crossref_primary_10_1111_crj_13568
crossref_primary_10_3390_jcm10050975
crossref_primary_10_1007_s00261_021_03337_9
crossref_primary_10_3390_cells9112392
crossref_primary_10_1007_s10286_020_00733_x
crossref_primary_10_1055_a_1687_2233
crossref_primary_10_1111_jth_15067
crossref_primary_10_1055_a_1581_6899
crossref_primary_10_1080_17474086_2020_1831383
crossref_primary_10_1080_00325481_2020_1823094
crossref_primary_10_1097_CCE_0000000000000354
crossref_primary_10_1097_CCE_0000000000000230
crossref_primary_10_1007_s00347_022_01676_6
crossref_primary_10_1016_j_advms_2021_12_001
crossref_primary_10_3390_ijerph20031949
crossref_primary_10_1016_j_ajem_2022_05_031
crossref_primary_10_1371_journal_pone_0302897
crossref_primary_10_1007_s10741_020_10016_2
crossref_primary_10_1186_s12886_022_02304_2
crossref_primary_10_1007_s00296_021_04873_9
crossref_primary_10_1097_MOH_0000000000000645
crossref_primary_10_1080_09537104_2021_1921721
crossref_primary_10_1097_HS9_0000000000000571
crossref_primary_10_1111_jch_14101
crossref_primary_10_1016_j_avsg_2022_04_048
crossref_primary_10_1016_j_ejphar_2023_175674
crossref_primary_10_1016_j_pdpdt_2022_102976
crossref_primary_10_1177_00469580221093442
crossref_primary_10_1016_j_advms_2022_02_001
crossref_primary_10_1055_a_1688_9398
crossref_primary_10_1007_s00580_021_03269_2
crossref_primary_10_1111_aji_13317
crossref_primary_10_1016_j_thromres_2022_11_028
crossref_primary_10_1002_rth2_12638
crossref_primary_10_1016_j_surg_2020_06_019
crossref_primary_10_1016_j_gene_2021_145471
crossref_primary_10_1016_j_radcr_2021_11_036
crossref_primary_10_1055_s_0041_1736166
crossref_primary_10_1016_j_advms_2022_10_002
crossref_primary_10_1186_s12936_022_04215_5
crossref_primary_10_1111_trf_16422
crossref_primary_10_4236_health_2022_142015
crossref_primary_10_1016_j_jddst_2022_103879
crossref_primary_10_1111_jth_14994
crossref_primary_10_1152_japplphysiol_00775_2020
crossref_primary_10_1016_j_ahj_2021_04_005
crossref_primary_10_1093_ehjcr_ytad628
crossref_primary_10_1097_CCM_0000000000005465
crossref_primary_10_1002_emp2_12730
crossref_primary_10_1177_0018578721990898
crossref_primary_10_1097_PRS_0000000000008177
crossref_primary_10_3389_fimmu_2021_649567
crossref_primary_10_3390_ijms24097683
crossref_primary_10_1016_j_critrevonc_2021_103529
crossref_primary_10_1186_s12931_025_03154_4
crossref_primary_10_3389_fcvm_2022_794092
crossref_primary_10_1002_rth2_12521
crossref_primary_10_3390_v14040811
crossref_primary_10_3390_ijms23063338
crossref_primary_10_1016_j_bvth_2024_100034
crossref_primary_10_1016_j_ijid_2020_08_023
crossref_primary_10_1016_j_amjcard_2020_08_040
crossref_primary_10_1002_jmv_28122
crossref_primary_10_7759_cureus_15650
crossref_primary_10_3390_diagnostics10100817
crossref_primary_10_1080_00325481_2021_1891788
crossref_primary_10_1186_s12959_020_00239_6
crossref_primary_10_1053_j_jvca_2021_02_057
crossref_primary_10_15406_jaccoa_2025_17_00620
crossref_primary_10_3390_hemato4040029
crossref_primary_10_1007_s11239_020_02318_x
crossref_primary_10_1007_s12185_020_03053_y
crossref_primary_10_1089_sur_2022_154
crossref_primary_10_1016_S0140_6736_21_01203_4
crossref_primary_10_3390_jcm10020191
crossref_primary_10_1186_s12959_021_00308_4
crossref_primary_10_3390_jcm10163522
crossref_primary_10_3390_jcm11010134
crossref_primary_10_1186_s12979_022_00309_5
crossref_primary_10_1016_j_jvsv_2020_08_030
crossref_primary_10_3390_jcm11195560
crossref_primary_10_1159_000524229
crossref_primary_10_1002_hsr2_1085
crossref_primary_10_1002_art_41690
crossref_primary_10_1186_s12959_021_00286_7
crossref_primary_10_1001_jamaophthalmol_2020_4988
crossref_primary_10_1136_bmj_n2400
crossref_primary_10_7759_cureus_30467
crossref_primary_10_1002_pbc_28975
crossref_primary_10_1016_j_rec_2020_12_009
crossref_primary_10_1016_j_ijbiomac_2021_10_144
crossref_primary_10_1053_j_jvca_2020_11_029
crossref_primary_10_3390_diagnostics13061069
crossref_primary_10_1213_ANE_0000000000006888
crossref_primary_10_1016_j_clindermatol_2021_07_001
crossref_primary_10_1186_s12967_023_04497_6
crossref_primary_10_5937_afmnai40_41219
crossref_primary_10_1164_rccm_202106_1514OC
crossref_primary_10_1055_s_0041_1722992
crossref_primary_10_1186_s12959_021_00331_5
crossref_primary_10_1007_s12072_020_10087_1
crossref_primary_10_3390_nu13072216
crossref_primary_10_1055_a_1562_7599
crossref_primary_10_1038_s41598_025_99786_z
crossref_primary_10_3389_fneur_2020_01031
crossref_primary_10_3390_jcm13185599
crossref_primary_10_3390_jcm11030860
crossref_primary_10_1177_20587392211029081
crossref_primary_10_1186_s12959_021_00268_9
crossref_primary_10_1016_j_jtcvs_2020_06_054
crossref_primary_10_1080_08923973_2021_1988102
crossref_primary_10_3233_CH_221664
crossref_primary_10_4239_wjd_v12_i7_1026
crossref_primary_10_1177_1076029620945398
crossref_primary_10_1007_s10238_023_01150_w
crossref_primary_10_3389_fcvm_2020_00129
crossref_primary_10_1016_j_ijmedinf_2022_104835
crossref_primary_10_3748_wjg_v27_i26_4143
crossref_primary_10_1038_s41392_020_00454_7
crossref_primary_10_1016_j_sexol_2022_03_002
crossref_primary_10_3390_biomedicines9080864
crossref_primary_10_1016_S0140_6736_20_31912_7
crossref_primary_10_1016_j_tru_2022_100098
crossref_primary_10_5315_wjh_v10_i1_1
crossref_primary_10_1136_bmjopen_2021_051971
crossref_primary_10_1097_CCE_0000000000000177
crossref_primary_10_3390_v13081620
crossref_primary_10_3390_ijms22063184
crossref_primary_10_1002_ccr3_3442
crossref_primary_10_3390_antiox9100936
crossref_primary_10_4330_wjc_v13_i8_299
crossref_primary_10_1016_j_micpath_2024_106558
crossref_primary_10_3390_ijms24054319
crossref_primary_10_1097_SHK_0000000000002406
crossref_primary_10_4330_wjc_v13_i8_298
crossref_primary_10_1055_s_0041_1722847
crossref_primary_10_3233_CH_221635
crossref_primary_10_1016_j_jcrc_2023_154344
crossref_primary_10_1007_s41030_020_00126_5
crossref_primary_10_1016_j_jacasi_2022_09_005
crossref_primary_10_3389_fcell_2022_914891
crossref_primary_10_1136_bcr_2021_244181
crossref_primary_10_5493_wjem_v12_i4_53
crossref_primary_10_1136_bcr_2020_239781
crossref_primary_10_3322_caac_21635
crossref_primary_10_1080_17474086_2021_1875813
crossref_primary_10_1007_s10238_022_00876_3
crossref_primary_10_1016_j_biochi_2022_06_005
crossref_primary_10_1016_j_ijid_2020_10_074
crossref_primary_10_17116_kardio202417031329
crossref_primary_10_1111_1346_8138_16722
crossref_primary_10_1186_s13578_022_00750_5
crossref_primary_10_1007_s10238_022_00891_4
crossref_primary_10_1097_MCC_0000000000000817
crossref_primary_10_33678_cor_2021_001
crossref_primary_10_3390_diagnostics13223477
crossref_primary_10_3390_jcm12020478
crossref_primary_10_1097_MPH_0000000000002321
crossref_primary_10_1182_bloodadvances_2022008666
crossref_primary_10_3357_AMHP_6109_2022
crossref_primary_10_1016_j_jmii_2020_08_006
crossref_primary_10_1186_s13054_020_03399_z
crossref_primary_10_2147_IJGM_S399806
crossref_primary_10_1177_1076029621999099
crossref_primary_10_1097_CCE_0000000000000194
crossref_primary_10_4331_wjbc_v14_i4_72
crossref_primary_10_2174_0929867328666210506161543
crossref_primary_10_3390_v13030419
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1097/CCM.0000000000004458
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
EISSN 1530-0293
ExternalDocumentID 32467443
Genre Journal Article
Review
GroupedDBID ---
.-D
.3C
.55
.GJ
.XZ
.Z2
01R
0R~
1J1
354
3O-
40H
4Q1
4Q2
4Q3
53G
5GY
5RE
5VS
6J9
6PF
71W
77Y
7O~
AAAAV
AAAXR
AAGIX
AAHPQ
AAIQE
AAJCS
AAMOA
AAMTA
AAQKA
AAQQT
AARTV
AASCR
AASOK
AASXQ
AAUEB
AAWTL
AAXQO
AAYEP
ABASU
ABBUW
ABDIG
ABJNI
ABOCM
ABPPZ
ABPXF
ABVCZ
ABXVJ
ABXYN
ABZAD
ABZZY
ACCJW
ACDDN
ACDOF
ACEWG
ACGFO
ACGFS
ACILI
ACLDA
ACOAL
ACWDW
ACWRI
ACXJB
ACXNZ
ACZKN
ADFPA
ADGGA
ADHPY
ADNKB
AE3
AE6
AEBDS
AEETU
AENEX
AFBFQ
AFDTB
AFEXH
AFFNX
AFMBP
AFNMH
AFSOK
AFUWQ
AGINI
AHOMT
AHQNM
AHQVU
AHRYX
AHVBC
AI.
AIJEX
AINUH
AJCLO
AJIOK
AJNWD
AJNYG
AJZMW
AKCTQ
AKULP
ALKUP
ALMA_UNASSIGNED_HOLDINGS
ALMTX
AMJPA
AMKUR
AMNEI
AOHHW
AOQMC
BOYCO
BQLVK
BS7
BYPQX
C45
CGR
CS3
CUY
CVF
DIWNM
DU5
DUNZO
E.X
EBS
ECM
EEVPB
EIF
EJD
ERAAH
EX3
F2K
F2L
F2M
F2N
F5P
FCALG
FL-
FW0
GNXGY
GQDEL
H0~
HLJTE
HZ~
IKREB
IKYAY
IN~
IPNFZ
J5H
JF9
JG8
JK3
JK8
K-A
K-F
K8S
KD2
KMI
L-C
L7B
M18
N4W
N9A
NEJ
NPM
N~7
N~B
N~M
O9-
OAG
OAH
OB4
OBH
OCUKA
ODA
ODMTH
ODZKP
OHH
OHT
OHYEH
OL1
OLB
OLG
OLH
OLU
OLV
OLY
OLZ
ONV
OPUJH
ORVUJ
OUVQU
OVD
OVDNE
OVIDH
OVLEI
OVOZU
OWBYB
OWU
OWV
OWW
OWX
OWY
OWZ
OXXIT
P-K
P2P
PONUX
R58
RIG
RLZ
S4R
S4S
T8P
TEORI
TSPGW
V2I
VH1
VVN
W3M
WOQ
WOW
X3V
X3W
X7M
XXN
XYM
YFH
YOC
YOJ
ZCG
ZFV
ZGI
ZXP
ZY1
ZZMQN
~9M
7X8
ADKSD
ADSXY
ID FETCH-LOGICAL-c5688-f567bba6eecbe0bc4f6c54d5a3033d3a3d328889e9cb383463e49278e38a82d62
IEDL.DBID 7X8
ISICitedReferencesCount 419
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=00003246-202009000-00015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1530-0293
IngestDate Mon Sep 29 04:00:59 EDT 2025
Mon Jul 21 06:02:45 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 9
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5688-f567bba6eecbe0bc4f6c54d5a3033d3a3d328889e9cb383463e49278e38a82d62
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC7255402
PMID 32467443
PQID 2408195718
PQPubID 23479
ParticipantIDs proquest_miscellaneous_2408195718
pubmed_primary_32467443
PublicationCentury 2000
PublicationDate 2020-September
PublicationDateYYYYMMDD 2020-09-01
PublicationDate_xml – month: 09
  year: 2020
  text: 2020-September
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Critical care medicine
PublicationTitleAlternate Crit Care Med
PublicationYear 2020
References 32706558 - Crit Care Med. 2020 Oct;48(10):e988-e989
32931200 - Crit Care Med. 2020 Oct;48(10):e989-e990
32897666 - Crit Care Med. 2020 Nov;48(11):e1159-e1160
References_xml – reference: 32897666 - Crit Care Med. 2020 Nov;48(11):e1159-e1160
– reference: 32931200 - Crit Care Med. 2020 Oct;48(10):e989-e990
– reference: 32706558 - Crit Care Med. 2020 Oct;48(10):e988-e989
SSID ssj0014573
Score 2.709715
SecondaryResourceType review_article
Snippet Recent studies have reported a high prevalence of thrombotic events in coronavirus disease 2019. However, the significance of thromboembolic complications has...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 1358
SubjectTerms Anticoagulants - therapeutic use
Betacoronavirus
Blood Coagulation Disorders - epidemiology
Blood Coagulation Disorders - etiology
Blood Coagulation Disorders - prevention & control
Coronavirus Infections - complications
Coronavirus Infections - physiopathology
COVID-19
Disseminated Intravascular Coagulation - etiology
Female
Humans
Male
Pandemics
Platelet Aggregation Inhibitors - therapeutic use
Pneumonia, Viral - complications
Pneumonia, Viral - physiopathology
Pregnancy
Prevalence
SARS-CoV-2
Thromboembolism - etiology
Thrombophilia - etiology
Title Coagulopathy of Coronavirus Disease 2019
URI https://www.ncbi.nlm.nih.gov/pubmed/32467443
https://www.proquest.com/docview/2408195718
Volume 48
WOSCitedRecordID wos00003246-202009000-00015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEF7Uinjx_agvInjwEppmZ18nkWjxYEsPCr2F3c1GCpLUxhb8984mKZ4EwcDmFgiz89xv9htCbkCbiJk899SXJgSt0OYMd6HUioK0fs5kza7_LEYjOZmocXvgVrVtlSufWDvqrLT-jLznqbj6iqErvZt9hH5qlEdX2xEa66RDMZXxLV1i8oMiAKsRZjTqKIwwrq2uzinRS5JhQ13YPgBM_p5k1sFmsPvf39wjO22aGdw3erFP1lxxQLaGLZB-SG6TUr8t3ks_kPgrKPMg8UwGejmdL6rgoQFtAoza6oi8Dh5fkqewHZoQWsZR63PGhTGaO2eNi4yFnFsGGdMYq2hGNa4Yq17llDVYnQKnDlQspKNSyzjj8THZKMrCnZIASxObC82UpBrLTNDAjFEqy3jfOW2gS65XMkhRKT3SoAtXLqr0RwpdctIIMp017BkpZnBcANCzP3x9TrZjX9_WPV0XpJOjSbpLsmmXn9NqflXvNr5H4-E303CwvQ
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Coagulopathy+of+Coronavirus+Disease+2019&rft.jtitle=Critical+care+medicine&rft.au=Iba%2C+Toshiaki&rft.au=Levy%2C+Jerrold+H&rft.au=Levi%2C+Marcel&rft.au=Connors%2C+Jean+Marie&rft.date=2020-09-01&rft.eissn=1530-0293&rft.volume=48&rft.issue=9&rft.spage=1358&rft_id=info:doi/10.1097%2FCCM.0000000000004458&rft_id=info%3Apmid%2F32467443&rft_id=info%3Apmid%2F32467443&rft.externalDocID=32467443
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1530-0293&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1530-0293&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1530-0293&client=summon